Lenvatinib – A multikinase inhibitor for radioiodine-refractory differentiated thyroid cancer
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Lenvatinib – A multikinase inhibitor for radioiodine-refractory differentiated thyroid cancer
Authors
Keywords
-
Journal
JOURNAL OF ONCOLOGY PHARMACY PRACTICE
Volume 24, Issue 1, Pages 28-32
Publisher
SAGE Publications
Online
2016-11-18
DOI
10.1177/1078155216680119
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase I dose-escalation study of E7080, a multikinase inhibitor, in patients with advanced solid tumors
- (2017) J. J. Nemunaitis et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenvatinib: Role in thyroid cancer and other solid tumors
- (2016) Maria E. Cabanillas et al. CANCER TREATMENT REVIEWS
- 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
- (2016) Bryan R. Haugen et al. THYROID
- A phase 1 study of lenvatinib, multiple receptor tyrosine kinase inhibitor, in Japanese patients with advanced solid tumors
- (2015) Shinji Nakamichi et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Drug safety evaluation of lenvatinib for thyroid cancer
- (2015) Jolanta Krajewska et al. Expert Opinion On Drug Safety
- Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
- (2015) Martin Schlumberger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of lenvatinib (E7080) on the QTc interval: results from a thorough QT study in healthy volunteers
- (2014) Robert C. Shumaker et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Effect of Rifampicin on the Pharmacokinetics of Lenvatinib in Healthy Adults
- (2014) Robert C. Shumaker et al. CLINICAL DRUG INVESTIGATION
- Evaluation of the effects of formulation and food on the pharmacokinetics of lenvatinib (E7080) in healthy volunteers
- (2014) Robert Shumaker et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Influence of hepatic impairment on lenvatinib pharmacokinetics following single-dose oral administration
- (2014) Robert Shumaker et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Lenvatinib for the treatment of radioiodine-refractory follicular and papillary thyroid cancer
- (2014) Jolanta Krajewska et al. Expert Opinion on Orphan Drugs
- Phase 1 study of lenvatinib combined with carboplatin and paclitaxel in patients with non-small-cell lung cancer
- (2013) M Nishio et al. BRITISH JOURNAL OF CANCER
- A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC)
- (2013) Ana M. Molina et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours
- (2012) D S Boss et al. BRITISH JOURNAL OF CANCER
- Phase I Dose-Escalation Study and Biomarker Analysis of E7080 in Patients with Advanced Solid Tumors
- (2011) K. Yamada et al. CLINICAL CANCER RESEARCH
- Cell Signaling by Receptor Tyrosine Kinases
- (2010) Mark A. Lemmon et al. CELL
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More